𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chronic lymphocytic leukemia : Treatment options for patients with refractory disease

✍ Scribed by Marina Motta; William G. Wierda; Alessandra Ferrajoli

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
151 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Alemtuzumab as treatment for residual di
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
✍ Susan M. O'Brien; Hagop M. Kantarjian; Deborah A. Thomas; Jorge Cortes; Francis πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The objective of this study was to investigate the efficacy and safety of alemtuzumab, the humanized anti‐CD52 monoclonal antibody, in patients with B‐cell chronic lymphocytic leukemia and residual disease after chemotherapy. ## METHODS Forty‐one patients received alemt

Fludarabine and mitoxantrone for patient
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia
✍ Apostolia M. Tsimberidou; Michael J. Keating; Francis J. Giles; William G. Wierd πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 481 KB

## Abstract ## BACKGROUND The objective of the current study was to assess the efficacy of combination therapy with fludarabine and mitoxantrone in patients with B‐cell chronic lymphocytic leukemia (CLL). ## METHODS Eighty‐eight patients were treated with fludarabine 30 mg/m^2^ intravenously dai